Related Experiment Video

Updated: Jun 27, 2026

A High-throughput-compatible FRET-based Platform for Identification and Characterization of Botulinum Neurotoxin Light Chain Modulators
10:30

A High-throughput-compatible FRET-based Platform for Identification and Characterization of Botulinum Neurotoxin Light Chain Modulators

Published on: December 27, 2013

[Antitoxin treatments for necrotizing pneumonia due to Panton-Valentine leukocidin-secreting Staphylococcus aureus]

N Libert1, E Batjom, A Cirodde

  • 1Service d'anesthésie réanimation, hôpital d'instruction des armées du Val-de-Grâce, 74, boulevard de Port-royal, 75005 Paris, France. nicolaslibert@free.fr

Medecine Et Maladies Infectieuses
|December 5, 2008
PubMed

Insights

Panton-Valentine leukocidin (PVL) from Staphylococcus aureus causes severe necrotizing pneumonia in healthy individuals. This review explores PVL

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Toxicology

Background:

  • Staphylococcus aureus causes suppurative infections and toxigenic diseases.
  • Panton-Valentine leukocidin (PVL) is a toxin secreted by a subset of S. aureus strains.
  • PVL is associated with severe skin infections and necrotizing pneumonia, even in immunocompetent patients.

Purpose of the Study:

  • To review the physiopathological mechanisms of PVL-mediated diseases.
  • To discuss the therapeutic relevance of drugs targeting PVL.
  • To provide an overview of necrotizing pneumonia caused by PVL-secreting S. aureus.

Main Methods:

  • Literature review of studies on S. aureus, PVL, and necrotizing pneumonia.
  • Analysis of clinical presentations and pathogenic mechanisms.
  • Evaluation of in vitro data on potential therapeutic agents.

Main Results:

  • Necrotizing pneumonia presents with fever, hemoptysis, alveolar infiltrations, and leukopenia.
  • The condition can rapidly progress to toxic shock or refractory hypoxemia.
  • Several therapies targeting leukocidin have shown promise in vitro.

Conclusions:

  • PVL-producing S. aureus poses a significant threat, particularly causing severe pneumonia.
  • Understanding the pathophysiology is crucial for developing effective treatments.
  • Further research into anti-leukocidin therapies is warranted.

More Related Videos

Methods for Detecting Cytotoxic Amyloids Following Infection of Pulmonary Endothelial Cells by Pseudomonas aeruginosa07:27

Methods for Detecting Cytotoxic Amyloids Following Infection of Pulmonary Endothelial Cells by Pseudomonas aeruginosa

Published on: July 12, 2018

Related Concept Videos

Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Botulism01:22

Botulism

Botulism is a life-threatening neuroparalytic condition caused by botulinum neurotoxin, which is produced by the bacterium Clostridium botulinum, a Gram-positive, spore-forming, obligate anaerobe.In adults, the toxin enters the body in different ways: in foodborne botulism, the preformed toxin is absorbed in the intestine. In wound botulism, spores grow in injured tissue and release the toxin into the blood. Infant botulism differs mechanistically from adult forms. In infants, botulism commonly...
Diphtheria01:28

Diphtheria

Diphtheria is an acute, toxin-mediated infectious disease that primarily affects the upper respiratory tract. It is caused by Corynebacterium diphtheriae, a Gram-positive, pleomorphic rod that lacks spore-forming capability and exhibits a characteristic club-shaped morphology under microscopic examination. While C. diphtheriae can asymptomatically colonize mucosal surfaces, clinical disease manifests only when the bacterial strain is lysogenized by a specific β-corynephage. This phage...
Acute Pyelonephritis II: Diagnostic Studies and Management01:28

Acute Pyelonephritis II: Diagnostic Studies and Management

Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
Pharmaceutical Poisoning: Treatment Strategies01:26

Pharmaceutical Poisoning: Treatment Strategies

Treatment strategies for poisoning are a critical aspect of emergency medicine, focusing on preventing the absorption of toxins and enhancing their elimination. When a poisoning incident occurs, the first response is to halt exposure and decontaminate the patient, particularly through gastrointestinal (GI) methods if the poison was ingested.Gastrointestinal Decontamination Techniques:Activated charcoal is the cornerstone of GI decontamination. It works through adsorption, binding the toxin to...
Anticholinesterase Agents: Poisoning and Treatment01:26

Anticholinesterase Agents: Poisoning and Treatment

Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...